home

Roche details hit to Avastin price in Japan

EVENTSfiercepharma2016-04-21 13:39 Read   178

Expected price cuts for reimbursed drugs in Japan this year have riled domestic and foreign firms with exact details sparse until Roche on the first quarter earnings call gave a figure for oncology drug Avastin.

Remicade safe from biosimilar competition this year, says J&J

Commentspmlive2016-04-21 13:23 Read   83

Johnson & Johnson does not expect any biosimilar competition to its top product Remicade in the US this year, according to the firm's chief financial officer Dominic Caruso.

Boehringer Ingelheim returns to growth after US turnaround

EVENTSpmlive2016-04-21 11:25 Read   79

Boehringer Ingelheim made a return to growth last year after sales rose 11% to €14.8bn, largely thanks to a strong showing by its core prescription drug business in the US.

Covidien Oridion Labeled Capnostream 20 and Capnostream 20p Patient Monitor Battery Packs by Medtronic: Recall - Risk of Thermal Damage

HealthDrugs2016-04-21 11:19 Read   128

Medtronic is notifying customers worldwide of a voluntary recall for the battery pack used in its Covidien Oridion labeled Capnostream 20 and Capnostream 20p Patient Monitors.

Shortly after you become pregnant, you can plan for a host of significant physical and emotional changes.

HealthDRUGS2016-04-21 11:12 Read   81

The American Academy of Family Physicians says here's what you can expect:

BioMarin says hemophilia A gene therapy data 'encouraging'

Frontierfiercebiotech2016-04-21 10:56 Read   78

Badly in need of a win, BioMarin ($BMRN) released what it described as encouraging midstage data from a small study today showing its blood disorder gene therapy saw high factor VIII rates--but raised liver enzymes were noted.

With Sarepta’s fate uncertain, BioMarin CEO Bienaimé weighs the future of their Duchenne drug

EVENTSfiercebiotech2016-04-21 10:51 Read   75

NEW YORK--Come Monday, Sarepta will get a very clear idea of the odds it faces on finally achieving its years-long quest to gain an FDA approval of its Duchenne muscular dystrophy drug eteplirsen.

Roche, Pfizer lead $42M round for Second Genome’s PoC play in the microbiome

EVENTSfiercebiotech2016-04-21 10:46 Read   135

One of the pioneers in microbiome drug research is winding up for a mid-stage clinical drive after nailing a $42.6 million Series B led by the venture arms of Roche ($RHHBY) and Pfizer ($PFE).

Statement on Review of NIH Sterile Production Facilities

CommentsNIH2016-04-21 10:42 Read   71

In light of serious problems identified in the NIH Clinical Center Pharmaceutical Development Section last year, NIH launched a multifaceted effort to ensure that processes for patient safety and quality of care at the hospital are of the highest standards.

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

R&Dinvestor.lilly2016-04-21 10:39 Read   155

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of people with chronic heart failure.

Scientists propose treatment for severe lung diseases

Frontiereurekalert2016-04-21 10:34 Read   82

Researchers are developing a new drug to treat life-threatening lung damage and breathing problems in people with severe infections like pneumonia, those undergoing certain cancer treatments and premature infants with underdeveloped, injury prone lungs.

Enterome Raises €14.5 Million in Series C Financing Round Nestlé Health Science Invests alongside Existing Investors

EVENTSyahoo2016-04-21 10:26 Read   69

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that it has raised €14.5 million in a Series C financing round.